- What is NurExone Biologic's primary focus?
- NurExone Biologic is developing an EV-based drug platform to treat damage in the Central Nervous System, aiming to revolutionize recovery from nervous system injuries by regenerating and rewiring neurons.
- When did NurExone Biologic go public?
- NurExone Biologic went public on the TSXV in July 2022.
- What was the most recent funding round for NurExone Biologic?
- The most recent funding round for NurExone Biologic was in September 2025, raising $460,000.
- What is the total amount of funding NurExone Biologic has raised to date?
- NurExone Biologic has raised a total of $9,528,000 USD.
- What is the current employee count for NurExone Biologic?
- NurExone Biologic has 11-50 employees.
- What was a significant patent allowance NurExone Biologic received in 2025?
- In September 2025, NurExone Biologic received a U.S. Patent Allowance for Exosome Manufacturing, which strengthens its supply chain readiness.
- What is NurExone Biologic's plan for U.S. manufacturing?
- In September 2025, NurExone Biologic announced plans to establish its first U.S. Commercial Manufacturing Facility in Indiana.
- What recent preclinical study results did NurExone Biologic announce regarding vision recovery?
- In October 2025, NurExone Biologic demonstrated reproducible, dose-dependent vision recovery in a preclinical glaucoma model.
- What strategic move did NurExone Biologic make in February 2025 regarding U.S. operations?
- In February 2025, NurExone Biologic formed Exo-Top Inc. in the U.S. for exosome manufacture and commercialization.
- What recognition did NurExone Biologic receive in March 2025?
- In March 2025, NurExone Biologic was recognized as a 2025 TSX Venture 50™ Top Performing Stock.
